An Overview of the “Visionary” Study: A Phase 3 Trial of Sibeprenlimab for IgA Nephropathy
Time: 4:30 pm
day: Day One
Details:
- Explore the current approach to IgAN treatment
- Understand the need for new therapies for IgAN
- Examine the role of the APRIL pathway in the pathogenesis of IgAN
